Lesinurad sodium. Solute carrier family 22 member 12 (URAT1) inhibitor, uricosuric, treatment of gout

Drugs of the Future

Volumn 36, Issue 12, 2011, Pages 875-880

  Pema, K M ^a  

^a Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FEBUXOSTAT; LESINURAD; PROBENECID; PROTEIN; RDEA 806; SULFINPYRAZONE; UNCLASSIFIED DRUG; URATE ANION EXCHANGER 1; URIC ACID; XANTHINE OXIDASE INHIBITOR;

ABDOMINAL PAIN; ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEATH; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GOUT; HEADACHE; HUMAN; MOUTH PAIN; NONHUMAN; SIDE EFFECT; SORE THROAT; URIC ACID BLOOD LEVEL;

EID: 84952975946     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.12.1665561     Document Type: Article

References (28)

1. Miner, J., Quart, B.D., Girardet, J.-L. (Ardea Biosciences, Inc.). Treatment of gout. WO 201116852.
2. Quart, B.D., Girardet, J.-L., Gunic, E., Yeh, L.-T. (Ardea Biosciences, Inc.). Novel compounds and composition and methods of use. CA 2706858, CN 01918377, EP 2217577, JP 2011504935, KR 2010085195, US 2009197825, US 2011268801, WO 009070740.
3. Zamansky, I., Galvin, G., Girardet, J.-L. (Ardea Biosciences, Inc.). Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4- cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, and uses thereof. WO 2011085009.
4. Liu, X., Hong, D., Wu, X. (Taizhou Hwasun Pharm. & Chem. Co., Ltd.). Method for preparing 4-cyclopropyl-1-isothiocyanonaphthalene and intermediate 4-cyclopropyl-1-naphthaldehyde oxime/halide. CN 102040546.
5. Zhu, Y., Pandya, B.J., Choi, H.K. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011, 63(10): 3136-41.
6. Choi, H.K., Mount, D.B., Reginato, A.M. Pathogenesis of gout. Ann Intern Med 2005, 143(7): 499-516. (Pubitemid 41379398)
7. Terkeltaub, R., Bushisky, D.A., Becker, M.A. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 2006, 8(Suppl. 1): S4.
8. Mount, D.B., Kwon, C.Y., Zandi-Nejad, K. Renal urate transport. Rheum Dis Clin North Am 2006, 32(2): 313-31. (Pubitemid 43728821)
9. Wyngaarden, J.B., Kelly, W.N. Disposition of uric acid in primary gout. In: Wyngaarden, J.B., Kelley, W.N. (Eds.). Gout and Hyperuricemia. New York: Grune & Stratton, 1976, 149-57.
10. Simkin, P.A. New standards for uric acid excretion: Evidence for an inducible transporter. Arthritis Care Res 2003, 49(5): 735-6.
11. Anzai, N., Kanai, Y., Endou, H. New insights into renal transport of urate. Curr Opin Rheumatol 2007, 19(2): 151-7. (Pubitemid 46208773)
12. Enomoto, A., Kimura, H., Chairoungdu, A. et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002, 417(6887): 447-52. (Pubitemid 34563537)
13. Endou, H., Anzai, N. Urate transport across the apical membrane of renal proximal tubules. Nucleosides Nucleotides Nucleic Acids 2008, 27(6): 578-84. (Pubitemid 351948550)
14. Hagos, Y., Stein, D., Ugele, B., Burckhardt, G., Bahn, A. Human renal organic anion trasporter 4 operates an asymmetric urate trasporter. J Am Soc Nephrol 2007, 18(2): 430-9. (Pubitemid 46193309)
15. Augustin, R., Carayabbiooulos, M.O., Dowd, L.O., Phay, J.E., Moley, J.F., Moley, K.H. Identification and characterization of human glucose transporter- like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004, 279(16): 16229-36. (Pubitemid 38509316)
16. Vitart, V., Rudan, I., Hayward, C. et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008, 40(4): 437-42. (Pubitemid 351450879)
17. Anzai, N., Ichida, K., Jutabha, P. et al Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008, 283(40): 26834-8.
18. Caulfield, M.J., Munroe, P.B., O'Neill, D. et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008, 5: e197.
19. Dalbeth, N., Merriman, T. Crystal ball gazing: New therapeutic targets for hyperuricemia and gout. Rheumatology (Oxford) 2009, 48(3): 222-6.
20. Yeh, L., Tamal, I., Hamatake, R. et al. Mode of action of RDEA594 as a uric acid lowering agent in humans following multiple doses of its prodrug, RDEA806. Annu Eur Congr Rheumatol (EULAR) (June 11-14, Paris) 2008, Abst THU0357.
21. Yeh, L.-T., Shen, Z., Kerr, B. et al. RDEA594, a potent URAT1 inhibitor without affecting other important renal transporters OAT1 and OAT3. Annu Eur Congr Rheumatol (EULAR) (June 10-13, Copenhagen) 2009, Abst THU0452.
22. Yang, X., Dick, R., Borges, V. et al. Evaluation of drug-drug interaction potential between RDEA594, allopurinol and febuxostat in preclinical species. 73rd Annu Sci Meet Am Coll Rheumatol (Oct 16-21, Philadelphia) 2009, Abst 1102.
23. Yeh, L.-T., Shen, Z., Kerr, B. et al. Safety, pharmocokinetics, and serum uric acid lowering effect of RDEA594, a novel uricosuric agent, in healthy volunteers. Annu Eur Congr Rheumatol (EULAR) (June 10-13, Copenhagen) 2009, Abst THU0451.
24. th Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 2-5 M, Dallas) 2011, Abst PIII-81.
25. th Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 2-5 M, Dallas) 2011, Abst PIII-80.
26. Perez-Ruiz, F, Hingoran, Welp J, et al. Efficacy and safety of RDEA594, a novel uricosuric agent, as combination therapy with allopurinol in gout patients: Randomized, double-blind, placebo-controlled, phase 2 experience. Annu Eur Congr Rheumatol (EULAR) (June 16-19, Rome) 2010, Abst SAT0375.
27. Yeh, L., Shen, Z., Kerr, B. et al RDEA594, a novel uricosuric agent, shows impressive reductions in serum urate levels as monotherapy and substantial additive activity in combination with febuxostat in normal healthy volunteers. Annu Eur Congr Rheumatol (EULAR) (June 16-19, Rome) 2010, Abst SAT0381.
28. th Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 2-5 M, Dallas) 2011, Abst PIII-79.